Physician profile
Mark Cruciani
NPI 1235171646
$3,314.96
in general payments reported to CMS, 2019-2025
21 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $285 · 2021: $429 · 2022: $525 · 2023: $701 · 2024: $676 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,188.66 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $703.95 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Glaxosmithkline, LLC. | $444.45 | 2022-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.64 | 2023-2024 | Cyltezo |
| Novartis Pharmaceuticals Corporation | $151.81 | 2020-2023 | |
| Janssen Biotech, INC. | $89.25 | 2022-2025 | Tremfya |
| Ucb, INC. | $84.36 | 2024-2025 | Bimzelx, Cimzia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.54 | 2023-2024 | Relistor |
| Astrazeneca Pharmaceuticals LP | $62.08 | 2022-2023 | Saphnelo |
| Sobi, INC | $59.64 | 2023-2025 | |
| Radius Health, INC. | $58.33 | 2023-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $50.42 | 2019-2024 | Orencia |
| Collegium Pharmaceutical, INC. | $40.22 | 2022 | |
| Genentech USA, INC. | $20.68 | 2023 | Actemra |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.92 | 2023 | |
| Daiichi Sankyo INC. | $16.26 | 2019 | |
| Pfizer INC. | $15.20 | 2021 | |
| Mallinckrodt Enterprises LLC | $12.97 | 2019 | |
| Horizon Therapeutics Plc | $12.83 | 2022 | |
| Eisai INC. | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cruciani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.